Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Ludwig-Maximilians - University of Munich
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Secondary Malignant Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Panitumumab (this asset) | Ludwig-Maximilians - University of Munich | P2 | CCC · 53 |
| Capecitabine | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Sacubitril Valsartan | Silesian Centre for Heart Diseases | P4 | BB |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Irinotecan | Ludwig-Maximilians - University of Munich | P2 | BB |
| Ex Vivo-Activated Autologous Lymph Node Lymphocytes | M.D. Anderson Cancer Center | P2 | B |
| Cetuximab | Ludwig-Maximilians - University of Munich | P2 | B |
| Bicalutamide | Gynaecologisch Oncologisch Centrum Zuid | P2/3 | B |
| Letrozole | Gynaecologisch Oncologisch Centrum Zuid | P2/3 | B |
+13 more in the Secondary Malignant Neoplasm cohort
Other indications for Panitumumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P2 | BBB · 73 |
| Colorectal Cancer | — | P3 | BB · 68 |
| Rectal Carcinoma | — | P2 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CapecitabineSixth Affiliated Hospital, Sun Yat-sen UniversityBB
- Sacubitril ValsartanSilesian Centre for Heart DiseasesBB
- OxaliplatinSixth Affiliated Hospital, Sun Yat-sen UniversityBB
- IrinotecanLudwig-Maximilians - University of MunichBB
- Ex Vivo-Activated Autologous Lymph Node LymphocytesM.D. Anderson Cancer CenterB
Citation
Floatz Terminal. Panitumumab in Secondary Malignant Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/panitumumab-secondary-malignant-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →